Burkhardt U, Mertens T, Eggers H J
Institut für Virologie, Universität zu Köln, Federal Republic of Germany.
J Med Virol. 1987 Nov;23(3):217-24. doi: 10.1002/jmv.1890230303.
Serum specimens were tested for HIV antibodies by two commercially available ELISAs (Abbott HTLV III EIA and Du Pont HTLV III-ELISA). The specificity and sensitivity of these assays were determined by comparison with indirect immunofluorescence and Western blot analysis. Specificity ranged from 94.3% in the Abbott assay to 97.9% in the Du Pont-ELISA. The sensitivity was 100% in the Abbott-ELISA and 99% in the Du Pont test. With both tests, false-positive results occurred predominantly in sera from patients with immunological disorders (kidney transplant recipients, lymphoma, Stevens-Johnson syndrome, etc.), whereas symptomatic AIDS-patients, patients with ARC, and persons with a defined risk for HIV infection could be diagnosed unequivocally. Specificity and sensitivity of anti-HIV ELISAs seemed to depend not only on definition of the cutoff value but also on other factors, such as antigen preparation and inactivation measures. Testing of ELISA-reactive sera by confirmatory tests remains necessary.
采用两种市售酶联免疫吸附测定法(雅培HTLV III酶免疫测定法和杜邦HTLV III - 酶联免疫吸附测定法)对血清标本进行HIV抗体检测。通过与间接免疫荧光法和蛋白质印迹分析相比较来确定这些检测方法的特异性和灵敏度。特异性范围从雅培检测法的94.3%到杜邦酶联免疫吸附测定法的97.9%。雅培酶联免疫吸附测定法的灵敏度为100%,杜邦检测法的灵敏度为99%。两种检测中,假阳性结果主要出现在免疫功能紊乱患者(肾移植受者、淋巴瘤、史蒂文斯 - 约翰逊综合征等)的血清中,而有症状的艾滋病患者、艾滋病相关综合征患者以及有明确HIV感染风险的人能够被明确诊断。抗HIV酶联免疫吸附测定法的特异性和灵敏度似乎不仅取决于临界值的定义,还取决于其他因素,如抗原制备和灭活措施。通过确证试验检测酶联免疫吸附测定反应性血清仍然是必要的。